Pre-made Vedolizumab benchmark antibody ( Whole mAb, anti-ITGA4;ITGB7 therapeutic antibody, Anti-CD49D/IA4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Vedolizumab benchmark antibody (Whole mAb, anti-ITGA4;ITGB7 therapeutic antibody, Anti-CD49D/IA4 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Millennium Pharmaceuticals, Inc (currently named Takeda Oncology, a subsidiary of Takeda Pharmaceuticals) for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7). Blocking the α4β7 integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name Entyvio.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-616-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Vedolizumab biosimilar, Whole mAb, Anti-ITGA4;ITGB7 Antibody: Anti-CD49D/IA4 therapeutic antibody
INN Name	Vedolizumab
Target	ITGA4_ITGB7
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2008
Year Recommended	2009
Companies	Medical College of Wisconsin;Millennium Pharmaceuticals;Takeda;Takeda Oncology
Conditions Approved	Crohn's disease;Ulcerative colitis
Conditions Active	Graft-versus-host disease;Coeliac disease
Conditions Discontinued	Malignant melanoma
Development Tech	na